FrancophonIA/ELRC3.0 huggingface dataset:
English: Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; problems with speech; slow heart rate; sensitivity to sunlight; bleeding from nose; abdominal distension; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth.
Slovenian: Občasni neželeni učinki (ki se lahko pojavijo pri 1 največ od 100 bolnikov) vključujejo preobčutljivost (npr. otekanje v ustih in grlu, srbenje, izpuščaj); sladkorno bolezen ali poslabšanje sladkorne bolezni, občasno povezano s ketoacidozo (ketoni v krvi in urinu) ali komo; epileptične napade, po navadi povezane z epileptičnimi napadi (epilepsijo) v preteklosti; mišično okorelost ali krče (vključno z obračanjem zrkel); sindrom nemirnih nog; težave z govorom; počasen srčni utrip; občutljivost za sončno svetlobo; krvavenje iz nosu; trebušno napihnjenost; izgubo spomina ali pozabljivost; urinsko inkontinenco; nezmožnost uriniranja; izgubo dlak; odsotno ali zmanjšano menstruacijo in spremembe dojk pri moških in ženskah, kot sta nenormalna tvorba mleka ali nenormalna rast.
English: Olanzapine - Restless legs syndrome (EPITT no 18659)
Slovenian: Olanzapin - sindrom nemirnih nog (EPITT št. 18659)
English: In case of AGEP diagnosis, flucloxacillin should be discontinued and any subsequent administration of flucloxacillin contra-indicated.
Slovenian: V primeru diagnoze AGEP je treba prenehati z jemanjem flukloksacilina in tudi vsaka nadaljnja uporaba flukloksacilina je kontraindicirana.
English: SmPC of all corticosteroids other than beclomethasone (excluding cutaneous formulations) - Double strikethrough represents deletion as compared to the PRAC recommendation published on the 26th September 2016.
Slovenian: Povzetek glavnih značilnosti zdravila za vse kortikosteroide razen beklometazona (brez kožnih formulacij) - dvojno prečrtano besedilo pomeni izbris v primerjavi s priporočilom odbora PRAC, objavljenim 26. septembra 2016.
English: Flucloxacillin - Acute generalized exanthematous pustulosis (AGEP)(EPITT no 18773)
Slovenian: Flukloksacilin - akutna generalizirana eksantematozna pustuloza (AGEP)(EPITT-št. 18773)
English: Undesirable effects (Table)
Slovenian: Neželeni učinki (preglednica)
English: Interaction not studied with any of the components of <product name>.
Slovenian: Medsebojno delovanje ni bilo proučevano z nobeno
English: Frequency not known: AGEP - acute generalized exanthematous pustulosis (see section 4.4)
Slovenian: Neznana pogostnost: AGEP - akutna generalizirana eksantematozna pustuloza (glejte poglavje 4.4)
English: Other side effects (frequency not known)
Slovenian: Drugi neželeni učinki (neznana pogostnost) Resne kožne reakcije
English: Package leaflet 4 - Possible side effects
Slovenian: Navodilo za uporabo 4 - Možni neželeni učinki
English: Summary of product characteristics (SmPC) of cobicistat containing products N.B: For Evotaz, Section 4.4 warning should be maintained.
Slovenian: Povzetek glavnih značilnosti zdravil , ki vsebujejo kobicistat OPOMBA: Pri zdravilu Evotaz je treba ohraniti opozorilo v poglavju 4.4. 4.5.
English: Beclomethasone is less dependent on CYP3A metabolism than some other corticosteroids, and in general interactions are unlikely; however the possibility of systemic effects with concomitant use of strong CYP3A inhibitors (e.g. ritonavir, cobicistat) cannot be excluded, and therefore caution and appropriate monitoring is advised with the use of such agents.
Slovenian: Beklometazon je manj odvisen od presnove s pomočjo encimov CYP3A kot nekateri drugi kortikosteroidi in na splošno medsebojno delovanje ni verjetno, vendar ni mogoče izključiti možnosti sistemskih učinkov pri sočasni uporabi močnih zaviralcev CYP3A (npr. ritonavirja, kobicistata), zato se pri uporabi tovrstnih učinkovin priporočata previdnost in ustrezno spremljanje.
English: Contact a doctor immediately if you get any of these symptoms.
Slovenian: Če se vam pojavijo navedeni simptomi, se takoj obrnite na zdravnika.
English: A red, scaly rash with bumps under the skin and blisters (exanthematous pustulosis).
Slovenian: Rdeč, luskast izpuščaj s podkožnimi bulicami in mehurji (eksantematozna pustuloza).
English: budesonide, fluticasone, mometasone, prednisone, triamcinolone).
Slovenian: kortikosteroide, vključno z betametazonom, budezonidom, flutikazonom, mometazonom, prednizonom, triamcinolonom.
English: fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression
Slovenian: presnavljajo s pomočjo encimov CYP3A (npr flutikazonpropionata in drugih inhaliranih ali nazalnih kortikosteroidov) lahko poveča tveganje za razvoj sistemskih kortikosteroidnih učinkov, vključno s Cushingovim sindromom in supresijo nadledvičnih žlez.
English: All corticosteroids other than beclomethasone (excluding cutaneous formulations)
Slovenian: Vsi kortikosteroidi razen beklometazona (brez kožnih formulacij)
English: Cobicistat containing products
Slovenian: Zdravila, ki vsebujejo kobicistat
English: PL of all corticosteroids other than beclomethasone (excluding cutaneous formulations)
Slovenian: Navodilo za uporabo za vse kortikosteroide razen beklometazona (brez kožnih formulacij)
English: Beclomethasone containing products (excluding cutaneous formulations)
Slovenian: Navodilo za uporabo za zdravil, ki vsebujejo beklometazon (brez kožnih formulacij)
English: Alternative corticosteroids which are less dependent on CYP3A metabolism e.g. beclomethasone for intranasal or inhalational use should be considered, particularly for long term use.
Slovenian: Zlasti pri dolgotrajnem jemanju je treba premisliti o uporabi alternativnih kortikosteroidov, ki so manj odvisni od presnove s pomočjo encimov CYP3A, npr. beklometazona za intranazalno uporabo ali inhaliranje.
English: Interaction with other medicinal products and other forms of interaction Corticosteroids primarily metabolised by CYP3A (including betamethasone,
Slovenian: Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Kortikosteroidi, ki se primarno presnavljajo s pomočjo
English: It is important to tell your doctor if you are taking: corticosteroids including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone.
Slovenian: Sočasna uporaba zdravila <ime zdravila> in kortikosteroidov, ki se encimov CYP3A (vključno z betametazonom, budezonidom, flutikazonom, mometazonom, prednizonom, triamcinolonom).
English: Package leaflet (PL) of cobicistat containing products
Slovenian: Navodilo za uporabo zdravil, ki vsebujejo kobicistat
English: Treatment lasts around 6 months, but not all the medicines are given every month.
Slovenian: Zdravljenje traja približno šest mesecev, vendar se vsa zdravila ne dajejo vsak mesec.
English: Unituxin dinutuximab
Slovenian: Unituxin dinutuksimab
English: The European Commission granted a marketing authorisation valid throughout the European Union for Unituxin on 14 August 2015.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Unituxin, veljavno po vsej Evropski uniji, izdala 14. avgusta 2015.
English: The daily dose depends on the child's body surface area, and infusions are given over 10 hours.
Slovenian: Dnevni odmerek je odvisen od otrokove telesne površine, infundiranje pa traja 10 ur.
English: Unituxin is given on four consecutive days each month, in the first 5 months.
Slovenian: Zdravilo Unituxin se v prvih petih mesecih daje vsak mesec štiri zaporedne dneve.
English: In addition, the company that markets Unituxin will carry out two studies to get more information about the safety of the medicine, including its long-term safety.
Slovenian: Poleg tega bo družba, ki trži zdravilo Unituxin, izvedla dve študiji, s katerima bo pridobila več informacij o varnosti zdravila, vključno z dolgoročno varnostjo.
English: What measures are being taken to ensure the safe and effective use of Unituxin?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Unituxin?
English: This is a summary of the European public assessment report (EPAR) for Unituxin.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Unituxin.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore concluded that Unituxin's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Unituxin večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: In this way, the medicine can help clear out cancer cells remaining in the body following other treatments.
Slovenian: Na ta način lahko zdravilo pomaga počistiti rakave celice, ki ostanejo v telesu po drugih oblikah zdravljenja.
English: Other information about Unituxin
Slovenian: Druge informacije o zdravilu Unituxin
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Slovenian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom izotretinoin, GM-CSF in interlevkin-2.
English: Patients with high-risk neuroblastoma need aggressive therapy, which is often not sufficient to prevent the cancer from returning.
Slovenian: Bolniki z nevroblastomom z visokim tveganjem potrebujejo agresivno zdravljenje, ki pogosto ni zadostno za preprečevanje ponovitve raka.
English: The most common side effects with Unituxin (seen in more than 30% of patients) are: pain affecting any part of the body, hypotension (low blood pressure), hypersensitivity (allergic reactions), fever, urticaria (hives), capillary leak syndrome (a condition whereby fluid leaks from the blood vessels causing swelling and a fall in blood pressure), anaemia (low red blood cell counts), low platelet counts, low sodium and potassium levels, raised liver enzymes and low levels of white blood cells.
Slovenian: Najpogostejši neželeni učinki zdravila Unituxin (ki so jih opazili pri več kot 30 % bolnikov) so: bolečina, ki prizadene kateri koli del telesa, hipotenzija (nizek krvni tlak), preobčutljivost (alergijske reakcije), povišana telesna temperatura, urtikarija (koprivnica), sindrom kapilarnega puščanja (stanje, pri katerem iz krvnih žil izteka tekočina, ki povzroča otekanje in padec krvnega tlaka), anemija (majhno število rdečih krvničk), majhno število trombocitov, nizke ravni natrija in kalija, povišane ravni jetrnih encimov in nizke ravni belih krvničk.
English: The number of patients who have to stop treatment because of side effects appears low and the side effects can be managed with appropriate measures.
Slovenian: Število bolnikov, ki so morali prekiniti zdravljenje zaradi neželenih učinkov, je majhno, neželene učinke pa je mogoče obvladovati z ustreznimi ukrepi.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Unituxin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Slovenian: Povzetek mnenja Odbora za zdravila sirote o zdravilu Unituxin je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: A risk management plan has been developed to ensure that Unituxin is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Unituxin je bil pripravljen načrt obvladovanja tveganj.
English: After around 3 years, 80% of patients receiving Unituxin were alive compared with 67% of patients receiving isotretinoin alone.
Slovenian: Po približno treh letih je preživelo 80 % bolnikov, ki so prejemali zdravilo Unituxin, in 67 % bolnikov, ki so prejemali izotretinoin kot samostojno zdravilo.
English: Although side effects with Unituxin can be severe, and medication is required to prevent allergic reactions and pain, the medicine's risks are considered acceptable given the severity of the disease.
Slovenian: Čeprav so lahko neželeni učinki zdravila Unituxin hudi in so potrebna zdravila za preprečevanje alergijskih reakcij ter bolečin, so tveganja zdravila sprejemljiva zaradi resnosti te bolezni.
English: When dinutuximab attaches to the gangliosides on neuroblastoma cells, it marks the cells out as targets for the immune system (the body's natural defences), which then attacks them.
Slovenian: Ko se dinutuksimab veže na gangliozide na celicah nevroblastoma, celice označi kot tarče za imunski sistem (naravni obrambni sistem telesa), ki jih nato napade.
English: It is not intended to provide practical advice on how to use Unituxin.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: Unituxin is a cancer medicine used to treat neuroblastoma, a nerve cell cancer, in children aged 12 months to 17 years.
Slovenian: Unituxin je zdravilo proti raku, ki se uporablja za zdravljenje nevroblastoma, raka živčnih celic, pri otrocih, starih od 12 mesecev do 17 let.
English: Unituxin is only for hospital use and treatment should be supervised by a doctor experienced in cancer treatments.
Slovenian: Zdravilo Unituxin je namenjeno samo uporabi v bolnišnici, zdravljenje pa mora nadzirati zdravnik z izkušnjami z zdravljenjem raka.
English: A study of Unituxin in combination with isotretinoin, GM-CSF and interleukin-2 showed that the combination can improve outcomes in these patients, keeping them alive for longer and helping to prevent the disease from returning or getting worse.
Slovenian: V študiji zdravila Unituxin v kombinaciji z izotretinoinom, GM-CSF in interlevkinom-2 so pokazali, da lahko ta kombinacija izboljša izide pri teh bolnikih, kar pomeni, da jih dlje ohranja pri življenju in pomaga preprečevati ponovitev ali poslabšanje bolezni.
English: Because of the risk of severe allergic reactions with Unituxin, equipment and staff should be immediately available to resuscitate the patient if reactions occur.
Slovenian: Zaradi tveganja hudih alergijskih reakcij na zdravilo Unituxin morata biti takoj na voljo oprema in osebje za oživljanje bolnika, če pride do take reakcije.
English: For more information about treatment with Unituxin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Unituxin preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Because the number of patients with neuroblastoma is low, the disease is considered ‘rare', and Unituxin was designated an ‘orphan medicine' (a medicine used in rare diseases) on 21 June 2011.
Slovenian: Ker je bolnikov z nevroblastomom malo, velja ta bolezen za redko, zato je bilo zdravilo Unituxin 21. junija 2011 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
English: What benefits of Unituxin have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Unituxin izkazalo v študijah?
English: What is Unituxin and what is it used for?
Slovenian: Kaj je zdravilo Unituxin in za kaj se uporablja?
English: Children treated with Unituxin will first have responded to chemotherapy and then received an additional treatment to clear out their bone marrow (myeloablative therapy) and a stemcell transplantation.
Slovenian: Otroci, zdravljeni z zdravilom Unituxin, se morajo najprej odzvati na kemoterapijo, potem pa prestati dodatno zdravljenje za prečiščenje kostnega mozga (mieloablacijsko terapijo) in presaditev matičnih celic.
English: Unituxin is used to treat children with ‘high-risk' neuroblastoma, the form of the cancer that has a high chance of returning.
Slovenian: Zdravilo Unituxin se uporablja za zdravljenje otrok z nevroblastomom z „visokim tveganjem“, tj. obliko raka, za katero obstaja velika možnost ponovitve.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Unituxin, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Unituxin in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: What are the risks associated with Unituxin?
Slovenian: Kakšna tveganja so povezana z zdravilom Unituxin?
English: Patients should also be given an antihistamine medicine before the start of each Unituxin infusion to reduce the risk of a reaction.
Slovenian: Pred začetkom vsakega infundiranja zdravila Unituxin je treba bolniku prav tako dati antihistaminik, da se zmanjša tveganje take reakcije.
English: The full EPAR and risk management plan summary for Unituxin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Unituxin sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Why is Unituxin approved?
Slovenian: Zakaj je bilo zdravilo Unituxin odobreno?
English: A main study conducted in 230 patients with high-risk neuroblastoma showed that Unituxin (given with isotretinoin, GM-CSF and interleukin-2) was more effective than isotretinoin alone at keeping patients alive and preventing the re-emergence of their cancer.
Slovenian: V glavni študiji, izvedeni pri 230 bolnikih z nevroblastomom z visokim tveganjem, so pokazali, da je bilo zdravilo Unituxin (ki se je dajalo z izotretinoinon, GM-CSF in interlevkinom-2) učinkovitejše kot samostojen izotretinoin pri ohranjanju bolnikov pri življenju in preprečevanju ponovnega pojava raka.
English: The active substance in Unituxin, dinutuximab, is a monoclonal antibody, designed to recognise and attach to a substance present at high levels in neuroblastoma cancer cells known as ganglioside GD2.
Slovenian: Zdravilna učinkovina v zdravilu Unituxin, dinutuksimab, je monoklonsko protitelo, ki prepoznava in se veže na snov, ki je v velikih koncentracijah prisotna v rakavih celicah nevroblastoma in se imenuje gangliozid GD2.
English: Because pain is a common side of Unituxin treatment, patients are also given pain killers.
Slovenian: Ker je bolečina pogost neželen učinek zdravljenja z zdravilom Unituxin, bodo bolniki prejeli tudi protibolečinska zdravila.
English: For practical information about using Unituxin, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Unituxin naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: The patient also receives 3 other medicines: isotretinoin,
Slovenian: Bolnik prejme tudi tri druga zdravila:
English: Unituxin is given in combination with 3 other medicines: GM-CSF, interleukin-2 and isotretinoin.
Slovenian: Zdravilo Unituxin se daje v kombinaciji s tremi drugimi zdravili: granulocitno-makrofagne kolonije stimulirajočim faktorjem (GM-CSF), interleukinom-2 in izotretinoinom.
English: Unituxin is given as an infusion (drip) into a vein.
Slovenian: Zdravilo Unituxin se daje z infundiranjem (kapalno infuzijo) v veno.
English: How does Unituxin work?
Slovenian: Kako zdravilo Unituxin deluje?
English: How is Unituxin used?
Slovenian: Kako se zdravilo Unituxin uporablja?
English: Unituxin contains the active substance dinutuximab.
Slovenian: Zdravilo Unituxin vsebuje zdravilno učinkovino dinutuksimab.
English: This overview was last updated in April 2019.
Slovenian: Ta povzetek je bil nazadnje posodobljen aprila 2019.
English: This will help protect the pig against the disease.
Slovenian: To pomaga zaščititi prašiča pred boleznijo.
English: In the future, the immune system will be able to react against the virus more quickly.
Slovenian: Tako bo v prihodnosti imunski sistem lahko hitreje reagiral proti njemu.
English: Further information on Suvaxyn PRRS MLV can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/suvaxyn-prrs-mlv.
Slovenian: Nadaljnje informacije o zdravilu Suvaxyn PRRS MLV so na voljo na spletni strani agencije: ema.europa.eu/medicines/veterinary/EPAR/suvaxyn-prrs-mlv
English: The European Medicines Agency decided that Suvaxyn PRRS MLV's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je odločila, da so koristi zdravila Suvaxyn PRRS MLV večje od z njim povezanih tveganj, in da se lahko odobri za uporabo v EU.
English: Mass vaccination can take place in herds in which presence of European PRRS virus is known.
Slovenian: Masovno cepljenje se lahko uporabi v čredah, kjer je ugotovljena prisotnost evropskega virusa PRRS.
English: The most common side effects with Suvaxyn PRRS MLV are a short lived increase in body temperature (0.5-0.8 °C on average), which may affect more than 1 in 10 pigs within 4 days of vaccination, and local reactions in the form of swellings which resolve without treatment in 5 to 9 days.
Slovenian: Najpogostejši neželeni učinki zdravila Suvaxyn PRRS MLV so kratkotrajen porast telesne temperature (v povprečju 0,5-0,8 C), ki lahko prizadene več kot 1 od 10 prašičev v štirih dneh po cepljenju, ter lokalne reakcije v obliki oteklin, ki izginejo brez zdravljenja v petih do devetih dneh.
English: When a pig is given the vaccine, the pig's immune system recognises the virus as ‘foreign' and makes antibodies against it.
Slovenian: Ko prašič prejme cepivo, imunski sistem prepozna virus kot „tujek“ in proti njemu tvori protitelesa.
English: Suvaxyn PRRS MLV received a marketing authorisation valid throughout the EU on 24 August 2017.
Slovenian: Zdravilo Suvaxyn PRRS MLV je pridobilo dovoljenje za promet, veljavno po vsej EU, 24. avgusta 2017.
English: Suvaxyn PRRS MLV must not be used in herds where European PRRS virus has not been detected by reliable diagnostic methods.
Slovenian: Zdravilo Suvaxyn PRRS MLV se ne sme uporabljati v čredah, kjer evropski virus PRRS ni bil odkrit z zanesljivimi diagnostičnimi metodami.
English: Gilts (female pigs that have not yet had piglets) and sows (female pigs that have had piglets) are given a single injection before introduction into the sow herd, about 4 weeks before breeding, and a booster injection every 6 months.
Slovenian: Svinjam mladicam (samicam, ki še niso imele prašičkov) in plemenskim svinjam (samicam, ki so že imele prašičke) se vbrizga enkratna injekcija pred vključitvijo v čredo plemenskih svinj, približno štiri tedne pred brejostjo, in obnovitveni odmerek vsakih šest mesecev.
English: Suvaxyn PRRS MLV contains a modified strain of live PRRS virus, strain 96V198, that has been weakened so that it does not cause disease.
Slovenian: Zdravilo Suvaxyn PRRS MLV vsebuje modificiran sev živega virusa PRRS, sev 96V198, ki je bil oslabljen, tako da ne povzroča bolezni.
English: There may also be disease of the airways which can lead to high death rates in suckling and weaned pigs.
Slovenian: Pojavi se lahko tudi bolezen dihal, ki lahko zviša umrljivost pri sesnih in odstavljenih prašičkih.
English: This viral disease of pigs may result in lowered farrowing (birth) rates, increase in abortions, stillborn, mummified as well as weak live born piglets and deaths.
Slovenian: Ta virusna bolezen lahko povzroči zmanjšanje števila prasitev, povečanje pojavov zvrgavanja, števila mrtvorojenih in mumificiranih prašičkov, slabotnih prašičkov ob rojstvu ter smrti.
English: For further information about using Suvaxyn PRRS MLV, see the package leaflet or contact your veterinarian or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Suvaxyn PRRS MLV glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.